{
  "denotations": [
    {
      "id": "T1",
      "obj": "Chemical",
      "span": {
        "begin": 33,
        "end": 40
      }
    },
    {
      "id": "T2",
      "obj": "Chemical",
      "span": {
        "begin": 19,
        "end": 30
      }
    },
    {
      "id": "T3",
      "obj": "Chemical",
      "span": {
        "begin": 43,
        "end": 54
      }
    },
    {
      "id": "T4",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 61,
        "end": 67
      }
    },
    {
      "id": "T5",
      "obj": "Disease",
      "span": {
        "begin": 113,
        "end": 136
      }
    },
    {
      "id": "T6",
      "obj": "Disease",
      "span": {
        "begin": 141,
        "end": 170
      }
    },
    {
      "id": "T7",
      "obj": "Gene_or_protein",
      "span": {
        "begin": 141,
        "end": 145
      }
    },
    {
      "id": "T8",
      "obj": "Chemical",
      "span": {
        "begin": 61,
        "end": 77
      }
    },
    {
      "id": "T9",
      "obj": "Chemical",
      "span": {
        "begin": 100,
        "end": 109
      }
    }
  ],
  "sourcedb": "PubMed",
  "sourceid": "26666244_1",
  "text": "A phase I study of selumetinib ( AZD6244 / ARRY-142866 ) , a MEK1/2 inhibitor , in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer ."
}
